{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T06:04:02Z","timestamp":1774418642918,"version":"3.50.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s10147-026-02985-5","type":"journal-article","created":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T11:02:50Z","timestamp":1771326170000},"page":"703-719","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative efficacy of immune checkpoint inhibitor-based regimens versus tyrosine kinase inhibitors in advanced hepatocellular carcinoma stratified by etiology: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0754-5682","authenticated-orcid":false,"given":"Tzu-Rong","family":"Peng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun-Hui","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ta-Wei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao-Chuan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuang-Yu","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ching-Sheng","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,17]]},"reference":[{"issue":"3","key":"2985_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL et al (2021) Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209\u2013249","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"2985_CR2","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet JM, Ricci S, Mazzaferro V et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359(4):378\u2013390","journal-title":"N Engl J Med"},{"issue":"10126","key":"2985_CR3","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","volume":"391","author":"M Kudo","year":"2018","unstructured":"Kudo M, Finn RS, Qin S et al (2018) Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 391(10126):1163\u20131173","journal-title":"Lancet"},{"key":"2985_CR4","doi-asserted-by":"crossref","unstructured":"Abou-Alfa GK, Lau G, Kudo M, et al (2022) Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. NEJM Evid 1(8):EVIDoa2100070","DOI":"10.1056\/EVIDoa2100070"},{"issue":"20","key":"2985_CR5","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn RS, Qin S, Ikeda M et al (2020) Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med 382(20):1894\u20131905","journal-title":"N Engl J Med"},{"issue":"10492","key":"2985_CR6","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1016\/S0140-6736(25)00403-9","volume":"405","author":"T Yau","year":"2025","unstructured":"Yau T, Galle PR, Decaens T et al (2025) Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial. Lancet 405(10492):1851\u20131864","journal-title":"Lancet"},{"key":"2985_CR7","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ejca.2022.11.017","volume":"180","author":"A Casadei-Gardini","year":"2023","unstructured":"Casadei-Gardini A, Rimini M, Tada T et al (2023) Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population. Eur J Cancer 180:9\u201320","journal-title":"Eur J Cancer"},{"issue":"4","key":"2985_CR8","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.3390\/biomedicines11041020","volume":"11","author":"F Pelizzaro","year":"2023","unstructured":"Pelizzaro F, Farinati F, Trevisani F (2023) Immune checkpoint inhibitors in hepatocellular carcinoma: current strategies and biomarkers predicting response and\/or resistance. Biomedicines 11(4):1020","journal-title":"Biomedicines"},{"key":"2985_CR9","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71","journal-title":"BMJ"},{"key":"2985_CR10","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366:l4898","journal-title":"BMJ"},{"key":"2985_CR11","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919","volume":"355","author":"JA Sterne","year":"2016","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC et al (2016) ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 355:i4919","journal-title":"BMJ"},{"issue":"3","key":"2985_CR12","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7(3):177\u2013188","journal-title":"Control Clin Trials"},{"issue":"6","key":"2985_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100591","volume":"7","author":"M Rimini","year":"2022","unstructured":"Rimini M, Rimassa L, Ueshima K et al (2022) Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis. ESMO Open 7(6):100591","journal-title":"ESMO Open"},{"issue":"2","key":"2985_CR14","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s11523-021-00803-8","volume":"16","author":"A Casadei-Gardini","year":"2021","unstructured":"Casadei-Gardini A, Tada T, Shimose S et al (2021) Is atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma superior even to lenvatinib? A matching-adjusted indirect comparison. Target Oncol 16(2):249\u2013254","journal-title":"Target Oncol"},{"issue":"11","key":"2985_CR15","doi-asserted-by":"publisher","DOI":"10.1097\/HC9.0000000000000562","volume":"8","author":"T de Castro","year":"2024","unstructured":"de Castro T, Welland S, Jochheim L et al (2024) Atezolizumab\/bevacizumab and lenvatinib for hepatocellular carcinoma: a comparative analysis in a European real-world cohort. Hepatol Commun 8(11):e0562","journal-title":"Hepatol Commun"},{"key":"2985_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1372007","volume":"14","author":"JW Han","year":"2024","unstructured":"Han JW, Sung PS, Yoo JS et al (2024) Differential liver function at cessation of atezolizumab-bevacizumab versus lenvatinib in HCC: a multicenter, propensity-score matched comparative study. Front Oncol 14:1372007","journal-title":"Front Oncol"},{"issue":"11","key":"2985_CR17","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1111\/apt.17441","volume":"57","author":"F Jost-Brinkmann","year":"2023","unstructured":"Jost-Brinkmann F, Demir M, Wree A et al (2023) Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: results from a German real-world cohort. Aliment Pharmacol Ther 57(11):1313\u20131325","journal-title":"Aliment Pharmacol Ther"},{"issue":"7","key":"2985_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14071747","volume":"14","author":"BK Kim","year":"2022","unstructured":"Kim BK, Cheon J, Kim H et al (2022) Atezolizumab\/bevacizumab vs. lenvatinib as first-line therapy for unresectable hepatocellular carcinoma: a real-world, multi-center study. Cancers (Basel) 14(7):1747","journal-title":"Cancers (Basel)"},{"issue":"2","key":"2985_CR19","doi-asserted-by":"publisher","first-page":"811","DOI":"10.62347\/BYIE2654","volume":"15","author":"YH Kuo","year":"2025","unstructured":"Kuo YH, Chen YH, Tsai MC et al (2025) Comparing health insurance-reimbursed lenvatinib and self-paid atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma. Am J Cancer Res 15(2):811\u2013823","journal-title":"Am J Cancer Res"},{"key":"2985_CR20","doi-asserted-by":"publisher","first-page":"81","DOI":"10.2147\/JHC.S432948","volume":"11","author":"R Mahn","year":"2024","unstructured":"Mahn R, Gl\u00fcer OA, Sadeghlar F et al (2024) First-line treatment for advanced hepatocellular carcinoma: a three-armed real-world comparison. J Hepatocell Carcinoma 11:81\u201394","journal-title":"J Hepatocell Carcinoma"},{"issue":"9","key":"2985_CR21","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1159\/000530028","volume":"101","author":"H Ohama","year":"2023","unstructured":"Ohama H, Hiraoka A, Tada T et al (2023) Comparison between atezolizumab plus bevacizumab and lenvatinib for hepatocellular carcinoma in patients with Child-Pugh class B in real-world clinical settings. Oncology 101(9):542\u2013552","journal-title":"Oncology"},{"issue":"7","key":"2985_CR22","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/S1470-2045(21)00252-7","volume":"22","author":"Z Ren","year":"2021","unstructured":"Ren Z, Xu J, Bai Y et al (2021) Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study. Lancet Oncol 22(7):977\u2013990","journal-title":"Lancet Oncol"},{"issue":"10","key":"2985_CR23","doi-asserted-by":"publisher","first-page":"7565","DOI":"10.1007\/s00432-023-04678-2","volume":"149","author":"M Rimini","year":"2023","unstructured":"Rimini M, Persano M, Tada T et al (2023) Survival outcomes from atezolizumab plus bevacizumab versus lenvatinib in Child Pugh B unresectable hepatocellular carcinoma patients. J Cancer Res Clin Oncol 149(10):7565\u20137577","journal-title":"J Cancer Res Clin Oncol"},{"issue":"7","key":"2985_CR24","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/S2468-1253(25)00059-7","volume":"10","author":"Y Shi","year":"2025","unstructured":"Shi Y, Han G, Zhou J et al (2025) Toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma (HEPATORCH): a randomised, open-label, phase 3 trial. Lancet Gastroenterol Hepatol 10(7):658\u2013670","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"6","key":"2985_CR25","doi-asserted-by":"publisher","first-page":"7077","DOI":"10.1002\/cam4.5506","volume":"12","author":"CW Su","year":"2023","unstructured":"Su CW, Teng W, Lin PT et al (2023) Similar efficacy and safety between lenvatinib versus atezolizumab plus bevacizumab as the first-line treatment for unresectable hepatocellular carcinoma. Cancer Med 12(6):7077\u20137089","journal-title":"Cancer Med"},{"issue":"9","key":"2985_CR26","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1111\/hepr.13797","volume":"52","author":"T Tanaka","year":"2022","unstructured":"Tanaka T, Hiraoka A, Tada T et al (2022) Therapeutic efficacy of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma in patients with Child-Pugh class A or B liver function in real-world clinical practice. Hepatol Res 52(9):773\u2013783","journal-title":"Hepatol Res"},{"key":"2985_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2022.109519","volume":"114","author":"BW Tian","year":"2023","unstructured":"Tian BW, Yan LJ, Ding ZN et al (2023) Evaluating liver function and the impact of immune checkpoint inhibitors in the prognosis of hepatocellular carcinoma patients: a systemic review and meta-analysis. Int Immunopharmacol 114:109519","journal-title":"Int Immunopharmacol"},{"issue":"3","key":"2985_CR28","first-page":"227","volume":"13","author":"A Pasta","year":"2023","unstructured":"Pasta A, Calabrese F, Jaffe A et al (2023) Safety and efficacy of atezolizumab\/bevacizumab in patients with hepatocellular carcinoma and impaired liver function: a systematic review and meta-analysis. Liver Cancer 13(3):227\u2013237","journal-title":"Liver Cancer"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-02985-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-026-02985-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-02985-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T05:12:37Z","timestamp":1774415557000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-026-02985-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,17]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["2985"],"URL":"https:\/\/doi.org\/10.1007\/s10147-026-02985-5","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,17]]},"assertion":[{"value":"7 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}